BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Meretek Diagnostics to Exhibit H. pylori Bacteria Test at 2007 DDW


5/16/2007 11:27:12 AM

LAFAYETTE, Colo., May 16 /PRNewswire/ -- Meretek Diagnostics, Inc. is exhibiting its BreathTek(TM) UBT (urea breath test) kit at the 2007 Digestive Disease Week (www.ddw.org). The conference is being held at the Washington Convention Center May 20 - 23 in Washington D.C.

BreathTek UBT is the only breath test available that is FDA cleared to test for both initial diagnosis and post-treatment monitoring of H. pylori infection in adults, an important pathogen in the upper GI tract of humans. The relationship between H. pylori and chronic active gastritis, duodenal ulcer, and gastric ulcer is well documented. Meretek Diagnostics will be exhibiting the test in booth 3351.

Overall, about one in three adults in the U.S. is infected with H. pylori.(1)

BreathTek(TM) UBT is intended for use in adult patients. The performance characteristics for persons under the age of eighteen (18) have not been established for this test.

The BreathTek(TM) UBT should not be used until four (4) weeks or more after the end of treatment for the eradication of H. pylori as earlier post-treatment assessment may give false negative results.

The BreathTek(TM) UBT is for administration by health care professionals. It is to be administered under a physician's supervision.

The test is simple, non-radioactive, and non-invasive. BreathTek UBT is 95 percent (95%) sensitive and specific, and is also used to confirm eradication 4 weeks following completion of treatment.(2)

For a complete listing of features and benefits of the BreathTek UBT, see the package insert at: http://www.meretek.com/downloads/2215NOV05_cropped.pdf

(1) Graham KS, Graham DY. Contemporary Diagnosis and Management of H. pylori-Associated Gastrointestinal Diseases. Newtown, PA: Handbooks in Health Care Co; 2002. (2) BreathTek(TM) UBT package insert. Lafayette, CO: Meretek Diagnostics; 2006.

About DDW

Digestive Disease Week is considered the largest and most prestigious meeting in the world for the GI professional. Every year it attracts more than 16,000 physicians, researchers and academics from around the world who desire to stay up-to-date in their respective fields. The meeting is the year's best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery; prevention, diagnosis and treatment of digestive disorders; and cutting-edge technological advances.

About Meretek Diagnostics

Located in Lafayette, Colo., Meretek Diagnostics, Inc. is an Otsuka Group company. Meretek was founded in 1993 by a group from the Baylor College of Medicine in Houston, Texas. The company holds exclusive licenses to patents involving the 13C urea breath test technologies.

For more information about Meretek Diagnostics, Inc. and the company's products, including prescribing information, warnings and limitations, visit the Meretek Web site at www.meretek.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

This release contains forward-looking statements, which reflect the Company's current expectations regarding future events. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are often identified by words such as "anticipate," "expect," "estimate," "intend," "project," "plan" and "believe." Forward-looking statements are subject to risks and uncertainties, including the difficulty of predicting FDA and other regulatory approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results, the protection of our intellectual property and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and Canadian securities regulators, including under the Canadian Multi-jurisdictional Disclosure System.

Meretek Diagnostics, Inc.

CONTACT: Dan Snyders, Vice President, PR Supervisor of Armada MedicalMarketing, +1-303-623-1190, ext. 230, dan@armadamedical.com, for MeretekDiagnostics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->